**S5 Fig. Predictive ability of OPN for CDAI remission in patients with RA who received TCZ with concomitant MTX**

(A) Logistic regression analysis showing association of increasing baseline osteopontin (OPN) levels with decreasing predicted probability of achieving Clinical Disease Activity Index (CDAI) remission at 1 year. (B) ROC curve showing a cut-off baseline OPN level of 17.3 ng/mL, discriminating between CDAI remission and non-remission at 1 year, with a sensitivity of 58% and a specificity of 81%.

**C:\Users\L\Documents\Dropbox\2014_EULAR\KEIO-TCZ-IFX\Paper\PLoS_ONE\revision\画像Fig\Supple_Fig\CDAI_OPN_prob_plot_ROC_MTX+.tif**